BME

BlackRock Health Sciences Trust

BlackRock Health Sciences Trust (BME) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Financial Services sector peers. Its strongest pillar is Growth (B+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C+
Factor Score 2.6 / 5.0
Growth
B+
Factor Score 3.7 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 7.3
EV / EBITDA 0.0
Rev Growth YoY 7.6%
Gross Margin N/M
Price Return 3M 12.5%
Price Return 12M 31.5%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 7.3
ROE 13.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.6) B+ (3.7) C+ (2.8) C+ (2.5) C- (1.9) C+ (2.7)
2026-08-04 C+ (2.6) B+ (3.7) C+ (2.8) B (3.2) C- (2.0) B- (2.9)
2026-08-03 C+ (2.6) C+ (2.8) C+ (2.7) B (3.2) C- (2.0) C+ (2.7)
2026-08-02 C+ (2.6) C+ (2.8) C+ (2.7) B (3.2) C- (1.9) C+ (2.6)